Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Financing › Details

Semalytix–SEVERAL: investment, 202008 financing round Series A €4.3m co-led by btov + Fly Ventures

 

Period Period 2020-08-31
Organisations Money taker Semalytix GmbH
  Money source SEVERAL
Product Product  venture capital
     

Semalytix GmbH. (8/31/20). "Press Release: Semalytix Closes Series A Investment Totaling €4.3m".

Semalytix today announced a € 4.3 M Series A investment led by the European investment firm btov and Seed investor Fly Ventures.

This investment has been a milestone in the company’s journey around becoming a leader in connecting authentic patient voices directly to Pharma by leveraging Tech such as Artificial Intelligence, Machine Learning, Natural Language Processing, and Data Story Telling. Semalytix’s AI-powered research platform Pharos turns evidence generation and patient listening into an on-demand service.

According to CEO and Co-Founder of Semalytix, Janik Jaskolski, Semalytix’s “vision is to help turn patient insights and patient-centricity into a real Northstar KPI in drug development.” Semalytix expresses gratitude towards all patients who have the courage to share their experiences. Mr. Jaskolski says: “Understanding your journeys is a crucial part in the development of new treatments and in improving care. Thank you.”

The focus of this investment is

> Deepening patient understanding of current Pharma clients

> Business development with new Pharma clients

> Collaborative refinement of the Semalytix Pharos Suite Semalytix is openly looking for partnerships with Pharma companies that put patients first.


About Semalytix:

At Semalytix, everything is about Patient Centricity. The company focuses on the questions “What would you do if you could listen to 1 billion authentic patient voices?” Semalytix allows Pharma companies to understand patient needs, treatment experiences, and disease burdens interactively and in a few clicks via their Semalytix Pharos Suite.

Their solution, the Semalytix Pharos Suite, is based on 3 pillars:

> Access to over 25 million public data sources.

> State-of-the-art Artificial Intelligence tech that detects patient-generated content with 98% precision and analyses that content at a speed of 2 1/2 books per minute.

> Intuitive dashboards that were developed with and for Pharma to access insights easily and share them quickly with the most relevant stakeholders.

Semalytix was founded in 2015 by Janik Jaskolski, Prof. Philipp Cimiano, and Dr. Matthias Hartung of the Semantic Computing Group at Bielefeld University. The company has grown to 70+ employees ranging from reputable AI to Pharma experts. Semalytix has so far successfully supported 5 Big Pharma companies on their journey towards more patient centricity.

   
Record changed: 2020-09-10

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Semalytix GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top